• Sun. Sep 19th, 2021

Sleeping Pill

  • Home
  • Assessing the Opportunities and Challenges in the Oncology Segment

Assessing the Opportunities and Challenges in the Oncology Segment

Oncology is the study of cancer and encompasses the diagnosis and treatment of cancer. The treatment of cancer requires a multidisciplinary approach which includes medications, surgical, and radiation. The type…

Follicular Lymphoma Market Size Anticipates Growth as the Key Companies Explores Novel Therapeutics Assets

Follicular lymphoma, a sub-type of indolent B cell non-Hodgkin lymphoma (NHL), accounts for approximately 20% of the total NHL cases. It is the most frequently diagnosed indolent lymphoma. On average,…

Series of FDA’s Approvals in ALS Drdeservesymphoma Space; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug,…

How Healthcare Apps are Adding New Perspectives to the Healthcare Industry?

The mobile app is one of the fine examples of communications systems. The mobile app comes in various forms and formats to meet the various needs of the user. We…

ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System

ADARx bags USD 75 Million to advance its RNA tech pipeline ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics, announced the completion of a USD 75 million Series B…